A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 246 participants.
Also called NCT05260411
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 246 participants
- Sponsor
- Registry
-
NCT05260411
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05260411. Randomized; quadruple masking; primary purpose treatment. Start 2022-01-26 (actual); primary completion 2022-12-19 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia
- Condition
- Hyperlipidemia
- Intervention (Biological)
- AK102
- Intervention (Biological)
- AK102
- Intervention (Drug)
- Placebo
- Lead sponsor
- Akeso
Record details
- Record id
cardio:ct-nct05260411- Content hash
f0afc7d3b65ad86d5b7c4d16bdad818f305c2423115578a061850ab2ad1f59d6